Top Biotech and Pharma Stocks to Bet on Cancer Cure & Control

The technicals do not look good at all – with a decline lasting over the past two months. He would not touch this one at all. A 50 day moving average would be a buy signal if it can trade back above it.

Likes turnarounds, but it’s not ready. Want to see two things: 1) the stock hitting a 52-week high, and 2) the numbers moving in the right direction. Don’t do anything until then. Odds are this is going to zero.

Brazilian order? He owns warrants and his wife works as a consultant for them. They have orders for 500 units for a melanoma testing product. The delivery is subject to approval by authorities in Brazil. This could lead to hardware sales by June and revenues that begin to show up in Q4. The company thinks…

Stockchase Research Editor: Michael O'Reilly AMGN just released earnings and the 12% increase in revenues and 5% increase in EPS were likely held back due to government mandates to focus health spending towards COVID-19 projects. The company is now benefitting from the release of new arthritis and metastatic colorectal cancer treatments. They also signed a…

(A Top Pick Dec 03/18, Up 47%) Celgene had made a number of mis-steps, including management applying for multiple FDA approvals. One thing he really liked about the acquisition was the price it was bought. The acquisition by BMY helped them diversify and it seems to be going well.

It was up nearly 4% today during JPMorgan's healthcare conference. BMY delivered good news. Management announced strong early revenue goals for new products, including three new drugs that could hit $4 billion in sales this decade. Their strong pipeline of drugs was bulked by buying Celgene and MyoKardia. They also announced a bullish free cash-flow…

An area that's started to act better recently. Well managed. But doesn't understand what the catalysts are. Doesn't find it compelling. Consider the picks and shovels instead, like Agilent or Danaher, who benefit from growth in everyone's pipeline.

All big pharmas have been treading water. Patent legislation left them with a leaky boat. He's gravitated toward the bio-pharmas. His favourite in that space is AbbVie, as it's good on fundamentals and financials, inexpensive, very fine dividend, great cashflow generator.

(A Top Pick Dec 16/19, Up 16%) Has gained some altitude. There has been no shortage of negative headlines over the years. Pharmaceuticals is a litigious industry in general. A well diversified company. A slower growth pharma company. However, it is a wonderful company looking at durability. Valuation is just above their buy price of…

A joint pharmaceutical company that has two businesses: branded and generic. The generic side will be very interesting post-covid when countries will be indebted and must provide cost-effective health care. The product pipeline looks reasonable. 6% dividend growth in the past 10 years. A safe steady growth opportunity. (Analysts’ price target is $102.00)

1-year outlook They've had a very good year like all pharmas, even in an election year. Pays a great yield and trades at a low multiple. Driving this are their COVID-19 vaccine efforts. They recently did a deal that puts them in MNRA which allows the fast-tracking of developing vaccines. This whole sector will continue…

Allan Tong’s Discover Picks The AZN stock currently trades at a 64x PE and pays a not-bad 2.69% dividend yield. It's trending $7 below its $59.73 price target, and has declined slightly to June levels. However, its PE has tumbled to levels last seen in December 2019. Three analysts rate it a strong buy, one…

They had good news about new drugs recently, but the stock still sold off. That's a sell signal.

Buy it under $500. It hasn't been in the news lately. They have a great Covid drug, but aren't making enough of it.

A small company that develops transformative gene medications. They are a small fish in a big sea. A recent transaction with a pharma company allows them to scale out their product, but it is still early. (Analysts’ price target is $58.05)

(A Top Pick Aug 29/14. Up 2.34%.) Radiation therapy equipment for treating cancer. Have been affected a little by foreign exchange rates. These are big ticket purchases, so she expects purchases have been delayed, but she has seen this come back. On the emerging-market side, it is a little bit more challenging. Still thinks the…

(A Top Pick Jan 30/20, Down 1%) Still likes. Continues to buy. Discount to other big pharma. Cancer drugs are very high margin. Pandemic has spurred pharma sales. Will benefit as life returns to normal. Yield is 3.1%.

He owns a basket. He owns this one for their oncology division. He has not owned it for anything COVID-related. Sometimes it is better to buy a basket of these companies.

ABT vs. JNJ Similar businesses. You absolutely need exposure to healthcare. He holds JNJ for the dividend aristocrat qualities. ABT has been impressive. Testing platform has been phenomenal and will continue to ramp up. It's a great addition to portfolios at these levels. Tough choice between the two, but ABT probably has more immediate upside.